HEALTH● LOW1h ago · Oct 25, 2026, 10:02 PM
Roche lung cancer drug extends survival by nearly six months in late-stage trial
Seeking Alpha Tech · global
A new lung cancer drug developed by Roche has shown in late-stage trials to extend patient survival by nearly six months. This represents a notable advancement in cancer treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH15m agoEli Lilly reports promising lung cancer drug resultsSeeking Alpha TechHEALTH39m agoUkraine receives over 230,000 doses of inactivated polio vaccineUkrinform [en]HEALTH1h agoJohnson & Johnson reports response rate for head, neck cancer treatmentSeeking Alpha TechHEALTH1h agoEbola: Day pandemic killed an Aláàfin, By Festus AdedayoPremium Times